Oxford study to screen newborns for spinal muscular atrophy
Evaluation study could bring nationwide SMA screening for newborns
A groundbreaking study led by the University of Oxford is set to evaluate the feasibility of introducing spinal muscular atrophy (SMA) screening for newborns across the UK, funded by the National Institute for Health and Care Research (NIHR).
The Service Evaluation for Newborn Screening for SMA (SENS) study aims to explore the practicality, acceptability, and impact of incorporating SMA screening into the NHS's existing newborn screening programme.
Scheduled to begin in August, the study could pave the way for nationwide implementation.
SMA, a severe genetic disorder, causes progressive muscle weakening and is potentially life-threatening in infants.
Early diagnosis and treatment can significantly improve outcomes due to the availability of new therapies in the UK.
Professor Laurent Servais of the University of Oxford’s Department of Paediatrics leads the study, which involves collaboration among UK universities, NHS laboratories, and patient organisations like SMA UK.
The programme plans to screen up to 755,000 newborns in England, generating robust evidence to guide national policy decisions.
Professor Servais highlighted the importance of early diagnosis, saying: "This study represents a decisive step towards ensuring that every child born with SMA in the UK has the opportunity to be diagnosed and treated before irreversible damage occurs.
"We now have therapies that can fundamentally change the trajectory of this disease if we can identify affected infants early.
"Our goal is to provide the evidence needed to support the introduction of SMA into routine newborn screening nationwide, ensuring equitable access for all families.'"
The SENS study will span seven NHS newborn screening laboratories, covering approximately two-thirds of births in England.
Researchers will use a phased approach for screening, allowing outcome comparisons between screened and unscreened populations.
Key aspects of the research include assessing the feasibility and acceptability of SMA screening, as well as evaluating clinical outcomes and economic impacts.
These findings will inform the UK National Screening Committee and NHS England about integrating SMA into the routine newborn blood spot programme.
Evidence from international and UK pilot studies suggests that SMA screening offers both clinical benefits and cost-effectiveness, reducing long-term healthcare expenses through earlier intervention and improved outcomes.
Giles Lomax, Chief Executive of SMA UK, said: "For families affected by SMA, time is everything.
"A diagnosis through newborn screening can mean the difference between a life limited by severe disability and one with far greater independence and opportunity."
The study reflects a broader move towards genomic technologies in healthcare, setting a precedent for potentially including more conditions in future NHS screening initiatives.
Results from the large-scale evaluation are expected in 2031, potentially shaping newborn screening policy nationwide.